Target Product Profile (TPP) for Chagas Disease Point-of-Care Diagnosis and Assessment of Response to Treatment

Autores
Porrás, Analía I.; Yadón, Zaida E.; Altcheh, Jaime Marcelo; Britto, Constança; Chaves, Gabriela C.; Flevaud, Laurence; Martins Filho, Olindo Assis; Ribeiro, Isabela; Schijman, Alejandro Gabriel; Shikanai-Yasuda, Maria Aparecida; Sosa-Estani, Sergio Alejandro; Stobbaerts, Eric; Zicker, Fabio
Año de publicación
2015
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Chagas disease, or American trypanosomiasis, affects 8 million people, largely in Latin America, where it is endemic in all countries. With an overall estimate of 65 million people at risk of contracting the disease, 28,000 new cases every year, and 12,000 deaths annually, Chagas disease is the most important parasitic disease in the Americas [1]. In addition, nonendemic countries such as the United States [2,3], Canada [4], Germany [5], Italy [6], Spain [7,8], Switzerland [9,10], and France [11] have experienced the occurrence of Trypanosoma cruzi?infected and Chagas disease cases; the majority of these cases are among immigrants coming from endemic Latin American countries [12]. Like other neglected tropical diseases (NTDs), Chagas disease affects mostly poor populations with limited access to health services. Vector transmission is associated with poor housing in periurban and rural areas. After infection, the disease is characterized by an acute phase, usually asymptomatic, which evolves in 20%?30% of the patients to a chronic disabling cardiac and/or digestive clinical form. The remaining infected individuals evolve to a chronic asymptomatic but infective clinical phase [13]. Reactivation of chronic Chagas disease may occur associated with comorbidities such as HIV/AIDS, organ transplants, or immunosuppressive therapy.
Fil: Porrás, Analía I.. Organización Panamericana de La Salud; Estados Unidos
Fil: Yadón, Zaida E.. Organización Panamericana de La Salud; Estados Unidos
Fil: Altcheh, Jaime Marcelo. Gobierno de la Ciudad de Buenos Aires. Hospital General de Niños "Ricardo Gutiérrez"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Britto, Constança. Instituto Oswaldo Cruz; Brasil
Fil: Chaves, Gabriela C.. Fundación Oswaldo Cruz; Brasil
Fil: Flevaud, Laurence. Médicos Sin Fronteras. Centro Operacional Barcelona-Atenas; España
Fil: Martins Filho, Olindo Assis. Instituto Oswaldo Cruz; Brasil
Fil: Ribeiro, Isabela. Drugs for Neglected Diseases initiative; Brasil
Fil: Schijman, Alejandro Gabriel. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres"; Argentina
Fil: Shikanai-Yasuda, Maria Aparecida. Universidade de Sao Paulo; Brasil
Fil: Sosa-Estani, Sergio Alejandro. Dirección Nacional de Instituto de Investigación. Administración Nacional de Laboratorio e Instituto de Salud “Dr. C. G. Malbrán”; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Stobbaerts, Eric. Drugs for Neglected Diseases initiative; Brasil
Fil: Zicker, Fabio. Fundación Oswaldo Cruz; Brasil
Materia
Chagas Disease
diagnosis
target product profile
diagnosis
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/41602
Acceder
id CONICETDig_e45466a55bbda2a7fb633eb7297af448
oai_identifier_str oai:ri.conicet.gov.ar:11336/41602
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Target Product Profile (TPP) for Chagas Disease Point-of-Care Diagnosis and Assessment of Response to TreatmentPorrás, Analía I.Yadón, Zaida E.Altcheh, Jaime MarceloBritto, ConstançaChaves, Gabriela C.Flevaud, LaurenceMartins Filho, Olindo AssisRibeiro, IsabelaSchijman, Alejandro GabrielShikanai-Yasuda, Maria AparecidaSosa-Estani, Sergio AlejandroStobbaerts, EricZicker, FabioChagas Diseasediagnosistarget product profilediagnosishttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1Chagas disease, or American trypanosomiasis, affects 8 million people, largely in Latin America, where it is endemic in all countries. With an overall estimate of 65 million people at risk of contracting the disease, 28,000 new cases every year, and 12,000 deaths annually, Chagas disease is the most important parasitic disease in the Americas [1]. In addition, nonendemic countries such as the United States [2,3], Canada [4], Germany [5], Italy [6], Spain [7,8], Switzerland [9,10], and France [11] have experienced the occurrence of Trypanosoma cruzi?infected and Chagas disease cases; the majority of these cases are among immigrants coming from endemic Latin American countries [12]. Like other neglected tropical diseases (NTDs), Chagas disease affects mostly poor populations with limited access to health services. Vector transmission is associated with poor housing in periurban and rural areas. After infection, the disease is characterized by an acute phase, usually asymptomatic, which evolves in 20%?30% of the patients to a chronic disabling cardiac and/or digestive clinical form. The remaining infected individuals evolve to a chronic asymptomatic but infective clinical phase [13]. Reactivation of chronic Chagas disease may occur associated with comorbidities such as HIV/AIDS, organ transplants, or immunosuppressive therapy.Fil: Porrás, Analía I.. Organización Panamericana de La Salud; Estados UnidosFil: Yadón, Zaida E.. Organización Panamericana de La Salud; Estados UnidosFil: Altcheh, Jaime Marcelo. Gobierno de la Ciudad de Buenos Aires. Hospital General de Niños "Ricardo Gutiérrez"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Britto, Constança. Instituto Oswaldo Cruz; BrasilFil: Chaves, Gabriela C.. Fundación Oswaldo Cruz; BrasilFil: Flevaud, Laurence. Médicos Sin Fronteras. Centro Operacional Barcelona-Atenas; EspañaFil: Martins Filho, Olindo Assis. Instituto Oswaldo Cruz; BrasilFil: Ribeiro, Isabela. Drugs for Neglected Diseases initiative; BrasilFil: Schijman, Alejandro Gabriel. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres"; ArgentinaFil: Shikanai-Yasuda, Maria Aparecida. Universidade de Sao Paulo; BrasilFil: Sosa-Estani, Sergio Alejandro. Dirección Nacional de Instituto de Investigación. Administración Nacional de Laboratorio e Instituto de Salud “Dr. C. G. Malbrán”; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Stobbaerts, Eric. Drugs for Neglected Diseases initiative; BrasilFil: Zicker, Fabio. Fundación Oswaldo Cruz; BrasilPublic Library of Science2015-06info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/41602Porrás, Analía I.; Yadón, Zaida E.; Altcheh, Jaime Marcelo; Britto, Constança; Chaves, Gabriela C.; et al.; Target Product Profile (TPP) for Chagas Disease Point-of-Care Diagnosis and Assessment of Response to Treatment; Public Library of Science; Neglected Tropical Diseases; 9; 6; 6-2015; 1-8;1935-2735CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4456144/info:eu-repo/semantics/altIdentifier/doi/10.1371%2Fjournal.pntd.0003697info:eu-repo/semantics/altIdentifier/url/http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0003697info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-17T10:43:51Zoai:ri.conicet.gov.ar:11336/41602instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-17 10:43:52.137CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Target Product Profile (TPP) for Chagas Disease Point-of-Care Diagnosis and Assessment of Response to Treatment
title Target Product Profile (TPP) for Chagas Disease Point-of-Care Diagnosis and Assessment of Response to Treatment
spellingShingle Target Product Profile (TPP) for Chagas Disease Point-of-Care Diagnosis and Assessment of Response to Treatment
Porrás, Analía I.
Chagas Disease
diagnosis
target product profile
diagnosis
title_short Target Product Profile (TPP) for Chagas Disease Point-of-Care Diagnosis and Assessment of Response to Treatment
title_full Target Product Profile (TPP) for Chagas Disease Point-of-Care Diagnosis and Assessment of Response to Treatment
title_fullStr Target Product Profile (TPP) for Chagas Disease Point-of-Care Diagnosis and Assessment of Response to Treatment
title_full_unstemmed Target Product Profile (TPP) for Chagas Disease Point-of-Care Diagnosis and Assessment of Response to Treatment
title_sort Target Product Profile (TPP) for Chagas Disease Point-of-Care Diagnosis and Assessment of Response to Treatment
dc.creator.none.fl_str_mv Porrás, Analía I.
Yadón, Zaida E.
Altcheh, Jaime Marcelo
Britto, Constança
Chaves, Gabriela C.
Flevaud, Laurence
Martins Filho, Olindo Assis
Ribeiro, Isabela
Schijman, Alejandro Gabriel
Shikanai-Yasuda, Maria Aparecida
Sosa-Estani, Sergio Alejandro
Stobbaerts, Eric
Zicker, Fabio
author Porrás, Analía I.
author_facet Porrás, Analía I.
Yadón, Zaida E.
Altcheh, Jaime Marcelo
Britto, Constança
Chaves, Gabriela C.
Flevaud, Laurence
Martins Filho, Olindo Assis
Ribeiro, Isabela
Schijman, Alejandro Gabriel
Shikanai-Yasuda, Maria Aparecida
Sosa-Estani, Sergio Alejandro
Stobbaerts, Eric
Zicker, Fabio
author_role author
author2 Yadón, Zaida E.
Altcheh, Jaime Marcelo
Britto, Constança
Chaves, Gabriela C.
Flevaud, Laurence
Martins Filho, Olindo Assis
Ribeiro, Isabela
Schijman, Alejandro Gabriel
Shikanai-Yasuda, Maria Aparecida
Sosa-Estani, Sergio Alejandro
Stobbaerts, Eric
Zicker, Fabio
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Chagas Disease
diagnosis
target product profile
diagnosis
topic Chagas Disease
diagnosis
target product profile
diagnosis
purl_subject.fl_str_mv https://purl.org/becyt/ford/1.6
https://purl.org/becyt/ford/1
dc.description.none.fl_txt_mv Chagas disease, or American trypanosomiasis, affects 8 million people, largely in Latin America, where it is endemic in all countries. With an overall estimate of 65 million people at risk of contracting the disease, 28,000 new cases every year, and 12,000 deaths annually, Chagas disease is the most important parasitic disease in the Americas [1]. In addition, nonendemic countries such as the United States [2,3], Canada [4], Germany [5], Italy [6], Spain [7,8], Switzerland [9,10], and France [11] have experienced the occurrence of Trypanosoma cruzi?infected and Chagas disease cases; the majority of these cases are among immigrants coming from endemic Latin American countries [12]. Like other neglected tropical diseases (NTDs), Chagas disease affects mostly poor populations with limited access to health services. Vector transmission is associated with poor housing in periurban and rural areas. After infection, the disease is characterized by an acute phase, usually asymptomatic, which evolves in 20%?30% of the patients to a chronic disabling cardiac and/or digestive clinical form. The remaining infected individuals evolve to a chronic asymptomatic but infective clinical phase [13]. Reactivation of chronic Chagas disease may occur associated with comorbidities such as HIV/AIDS, organ transplants, or immunosuppressive therapy.
Fil: Porrás, Analía I.. Organización Panamericana de La Salud; Estados Unidos
Fil: Yadón, Zaida E.. Organización Panamericana de La Salud; Estados Unidos
Fil: Altcheh, Jaime Marcelo. Gobierno de la Ciudad de Buenos Aires. Hospital General de Niños "Ricardo Gutiérrez"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Britto, Constança. Instituto Oswaldo Cruz; Brasil
Fil: Chaves, Gabriela C.. Fundación Oswaldo Cruz; Brasil
Fil: Flevaud, Laurence. Médicos Sin Fronteras. Centro Operacional Barcelona-Atenas; España
Fil: Martins Filho, Olindo Assis. Instituto Oswaldo Cruz; Brasil
Fil: Ribeiro, Isabela. Drugs for Neglected Diseases initiative; Brasil
Fil: Schijman, Alejandro Gabriel. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres"; Argentina
Fil: Shikanai-Yasuda, Maria Aparecida. Universidade de Sao Paulo; Brasil
Fil: Sosa-Estani, Sergio Alejandro. Dirección Nacional de Instituto de Investigación. Administración Nacional de Laboratorio e Instituto de Salud “Dr. C. G. Malbrán”; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Stobbaerts, Eric. Drugs for Neglected Diseases initiative; Brasil
Fil: Zicker, Fabio. Fundación Oswaldo Cruz; Brasil
description Chagas disease, or American trypanosomiasis, affects 8 million people, largely in Latin America, where it is endemic in all countries. With an overall estimate of 65 million people at risk of contracting the disease, 28,000 new cases every year, and 12,000 deaths annually, Chagas disease is the most important parasitic disease in the Americas [1]. In addition, nonendemic countries such as the United States [2,3], Canada [4], Germany [5], Italy [6], Spain [7,8], Switzerland [9,10], and France [11] have experienced the occurrence of Trypanosoma cruzi?infected and Chagas disease cases; the majority of these cases are among immigrants coming from endemic Latin American countries [12]. Like other neglected tropical diseases (NTDs), Chagas disease affects mostly poor populations with limited access to health services. Vector transmission is associated with poor housing in periurban and rural areas. After infection, the disease is characterized by an acute phase, usually asymptomatic, which evolves in 20%?30% of the patients to a chronic disabling cardiac and/or digestive clinical form. The remaining infected individuals evolve to a chronic asymptomatic but infective clinical phase [13]. Reactivation of chronic Chagas disease may occur associated with comorbidities such as HIV/AIDS, organ transplants, or immunosuppressive therapy.
publishDate 2015
dc.date.none.fl_str_mv 2015-06
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/41602
Porrás, Analía I.; Yadón, Zaida E.; Altcheh, Jaime Marcelo; Britto, Constança; Chaves, Gabriela C.; et al.; Target Product Profile (TPP) for Chagas Disease Point-of-Care Diagnosis and Assessment of Response to Treatment; Public Library of Science; Neglected Tropical Diseases; 9; 6; 6-2015; 1-8;
1935-2735
CONICET Digital
CONICET
url http://hdl.handle.net/11336/41602
identifier_str_mv Porrás, Analía I.; Yadón, Zaida E.; Altcheh, Jaime Marcelo; Britto, Constança; Chaves, Gabriela C.; et al.; Target Product Profile (TPP) for Chagas Disease Point-of-Care Diagnosis and Assessment of Response to Treatment; Public Library of Science; Neglected Tropical Diseases; 9; 6; 6-2015; 1-8;
1935-2735
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4456144/
info:eu-repo/semantics/altIdentifier/doi/10.1371%2Fjournal.pntd.0003697
info:eu-repo/semantics/altIdentifier/url/http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0003697
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Public Library of Science
publisher.none.fl_str_mv Public Library of Science
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1843605950791942144
score 13.000565

Publicaciones similares